Investors

Presentations

Title Date Documents

The Potential of RNAi Therapy in Ocular Disease at the 6th Ocular Diseases and Drug Development Conference

Clinical Development of RXI-109 to Prevent Dermal Scar Formation at AsiaTIDES

sd-rxRNA Demonstrate Robust Efficacy in the Eye at OIS@AAO

RXi Investor & Analyst Symposium

Clinical Development of RXI-109 to Reduce Dermal Scarring at IBC’s 15th Annual TIDES at the Oligonucleotide and Peptide Therapeutics Conference

Development of sd-rxRNA for Retinoblastoma Therapy at the ARVO Annual Meeting

Update on RXI-109: An RNAi Compound in Clinical Development to Reduce Dermal Scarring at IBC’s 5th Annual AsiaTIDES: Oligonucleotide and Peptide Research, Technology and Product Development

Local Delivery: Lessons Learned from ‘Self-Delivering’ RNAi Compounds at IBC’s 5th Annual AsiaTIDES: Oligonucleotide and Peptide Research, Technology and Product Development

Oligonucleotide-based Therapeutics: 20 Years from Concept to Clinical Validation at the Bio International Convention

Asymmetric, Hydrophobically Modified RNAi Compounds: From Mechanism to Clinical Development at Genomics Research 2012/RNAi and miRNA